Corcept Therapeutics has been granted a patent for methods of preparing specific compounds, including 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one. The patent also covers new intermediate compounds. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Corcept Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Method of preparing compound of formula i

Source: United States Patent and Trademark Office (USPTO). Credit: Corcept Therapeutics Inc

A recently granted patent (Publication Number: US11827608B2) discloses a method for preparing a compound of Formula I, involving specific reaction mixtures and solvents. The method includes steps such as dissolving the compound in a solvent mixture, heating, and cooling to form crystalline Formula I. Additionally, the patent details the preparation of a compound of Formula II in its monohydrate form through a series of reaction mixtures and solvents, including the use of guanidine and salts thereof. The method further involves the preparation of the compound of Formula III and IVa through specific reaction mixtures and solvents, highlighting the precise steps and components required for the synthesis process.

Furthermore, the patent outlines the preparation of a compound of Formula Va through a complex series of reaction mixtures involving various bases, solvents, and activating agents. The method includes steps such as forming a reaction mixture comprising isopropylidene malonate, a carboxyl coupling agent, a second amine base, and a compound of Formula VI. The patent also includes claims for the compounds of Formula II, IVa, and Va, emphasizing the novelty and utility of these chemical entities. Overall, the patent provides a detailed and comprehensive guide for synthesizing these compounds, offering valuable insights for researchers and professionals in the field of organic chemistry.

To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies